Barriers to insulin therapy remain a critical challenge for individuals with insulin-treated diabetes, contributing to suboptimal clinical outcomes. The Afrezza® inhaled insulin system, with Technosphere® insulin (TI), is a promising alternative to subcutaneous insulin injections, offering a rapid pharmacokinetic profile and ease of use. Clinical studies demonstrate comparable HbA1c reductions, fewer hypoglycemic events, and improved treatment satisfaction with TI compared with rapid-acting insulin analogs. By addressing barriers such as needle aversion, injection-related pain, and variable insulin absorption, TI has the potential to enhance diabetes treatment and quality of life. Individual choice, supported by shared decision-making, is essential for individualized diabetes care, empowering people with diabetes and improving outcomes. Broader adoption requires increased clinician awareness and insurance coverage.
Hood et al. (Sun,) studied this question.